M&A Deal Summary

ImmunogenX Acquires Alvine Pharmaceuticals

On March 15, 2016, ImmunogenX acquired life science company Alvine Pharmaceuticals

Acquisition Highlights
  • This is ImmunogenX’s 1st transaction in the Life Science sector.
  • This is ImmunogenX’s 1st transaction in the United States.
  • This is ImmunogenX’s 1st transaction in California.

M&A Deal Summary

Date 2016-03-15
Target Alvine Pharmaceuticals
Sector Life Science
Buyer(s) ImmunogenX
Deal Type Add-on Acquisition

Target

Alvine Pharmaceuticals

San Carlos, California, United States
Alvine Pharmaceuticals, Inc., is a privately held, clinical stage company developing biologics to target autoimmune/inflammatory diseases. Alvine’s lead product candidate, ALV003, is a mixture of two proteases engineered to degrade gluten. Gluten is the difficult to digest protein found in wheat, rye, and barley that triggers celiac disease in genetically susceptible individuals.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ImmunogenX

Newport Beach, California, United States

Category Company
Founded 2013
Sector Life Science
DESCRIPTION

is a clinical-stage company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research.ImmunogenX is extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there is no other effective diagnostic.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1